Percheron Therapeutics Ltd (AU:PER) — Market Cap & Net Worth
Market Cap & Net Worth: Percheron Therapeutics Ltd (PER)
Percheron Therapeutics Ltd (AU:PER) has a market capitalization of $6.16 Million (AU$8.70 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #27955 globally and #1498 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Percheron Therapeutics Ltd's stock price AU$0.01 by its total outstanding shares 1087437633 (1.09 Billion). Analyse Percheron Therapeutics Ltd (PER) cash conversion ratio to see how efficiently the company converts income to cash.
Percheron Therapeutics Ltd Market Cap History: 2015 to 2026
Percheron Therapeutics Ltd's market capitalization history from 2015 to 2026. Data shows change from $54.63 Million to $6.16 Million (-20.93% CAGR).
Percheron Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Percheron Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
117.94x
Percheron Therapeutics Ltd's market cap is 117.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $27.70 Million | $1.00 Million | -$2.51 Million | 27.70x | N/A |
| 2017 | $18.47 Million | $69.11K | -$2.75 Million | 267.18x | N/A |
| 2018 | $20.01 Million | $25.55K | -$2.33 Million | 782.98x | N/A |
| 2019 | $69.25 Million | $66.17K | -$2.94 Million | 1046.53x | N/A |
| 2020 | $100.03 Million | $30.53K | -$5.91 Million | 3276.32x | N/A |
| 2021 | $150.04 Million | $4.18K | -$8.06 Million | 35894.53x | N/A |
| 2022 | $74.63 Million | $34.18K | -$5.81 Million | 2183.58x | N/A |
| 2023 | $45.40 Million | $384.92K | -$11.38 Million | 117.94x | N/A |
Competitor Companies of PER by Market Capitalization
Companies near Percheron Therapeutics Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Percheron Therapeutics Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #498 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #524 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #534 globally with a market cap of $49.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #573 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #498 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #524 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #534 | Zoetis Inc | NYSE:ZTS | $49.60 Billion | $112.54 |
| #573 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.24 |
Percheron Therapeutics Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Percheron Therapeutics Ltd's market cap moved from $54.63 Million to $ 6.16 Million, with a yearly change of -20.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$6.16 Million | -11.11% |
| 2025 | AU$6.92 Million | +28.57% |
| 2024 | AU$5.39 Million | -88.14% |
| 2023 | AU$45.40 Million | -39.18% |
| 2022 | AU$74.63 Million | -50.26% |
| 2021 | AU$150.04 Million | +50.00% |
| 2020 | AU$100.03 Million | +44.44% |
| 2019 | AU$69.25 Million | +246.15% |
| 2018 | AU$20.01 Million | +8.33% |
| 2017 | AU$18.47 Million | -33.33% |
| 2016 | AU$27.70 Million | -49.30% |
| 2015 | AU$54.63 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Percheron Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.16 Million USD |
| MoneyControl | $6.16 Million USD |
| MarketWatch | $6.16 Million USD |
| marketcap.company | $6.16 Million USD |
| Reuters | $6.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Percheron Therapeutics Ltd
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals for cancer and rare diseases in Australia. The company's lead asset is ATL1102, an antisense oligonucleotide inhibitor of CD49d, which is in Phase IIb clinical trial for the treatment of Duchenne muscular dystrophy, multiple sclerosis, asthma, and other inflammatory indications. It also devel… Read more